Revolutionizing Medical Decision-Making
OpenEvidence, a specialized medical search engine, is changing the way U.S. doctors access and utilize medical information. In just one year since its launch, over a quarter of American physicians have turned to this AI-powered platform to make critical medical decisions. From selecting the most effective prostate cancer treatments to recognizing the symptoms of life-threatening conditions like pulmonary embolisms, OpenEvidence is proving to be a game-changer. The platform’s ability to help doctors in remote areas access expert-level guidance is particularly noteworthy, as it bridges the gap created by the shortage of sub-specialists.
The demand for a tool like OpenEvidence has never been greater, as the U.S. healthcare system faces increasing pressure. With only one million active physicians serving a rapidly growing and aging population of 340 million, doctors are often overburdened. In addition to patient care, they spend countless hours keeping up with the latest medical research. This challenge is compounded by the fact that a new PubMed article is published every three minutes, and medical knowledge doubles every 73 days. OpenEvidence streamlines this overwhelming information flow by searching across 35 million peer-reviewed publications and using advanced AI to deliver accurate, up-to-date medical insights.
The Technology Behind OpenEvidence
OpenEvidence is often compared to ChatGPT but tailored specifically for the medical field. It efficiently scans vast medical literature and presents findings in a conversational manner, complete with medical charts and graphs, ensuring doctors receive clear and relevant information. One of the platform’s key features is its accuracy; it refrains from giving uncertain answers when the literature is inconclusive, maintaining a high standard of reliability.
Co-founded by Daniel Nadler and Zachary Ziegler, OpenEvidence has rapidly gained traction due to its innovative approach. Nadler, a second-time founder, previously launched the financial technology platform Kensho, which was later acquired by S&P in 2018. His vision for OpenEvidence was inspired by the challenges posed during the COVID-19 pandemic, motivating him to apply his AI expertise to healthcare. Together with Zachary, a Harvard-trained computer scientist, Nadler has built a team of top AI researchers and a world-class medical advisory board, ensuring the platform meets the needs of modern healthcare professionals.
Rapid Growth and Future Prospects
OpenEvidence’s growth has been nothing short of extraordinary. In less than a year, it has become one of the fastest-growing healthcare startups, with over 35,000 verified doctors registering each month. This rapid adoption is fueled by word of mouth, a testament to the trust and credibility the platform has earned within the medical community. The app is free for all U.S. healthcare providers, making it accessible to doctors in both large hospitals and small, independent practices in rural areas.
The platform’s impact has caught the attention of major investors, with Sequoia leading its Series A funding round as the first institutional investor. The partnership aims to support OpenEvidence’s continued growth, helping it realize its potential to revolutionize medical decision-making and improve patient outcomes. The team behind OpenEvidence is poised to create one of the most influential healthcare companies of the decade, reshaping how doctors access and use medical knowledge.
